Fujirebio Diagnostics CA 19-9
This article was originally published in The Gray Sheet
First blood test for monitoring pancreatic cancer gains FDA market clearance, announced May 13. The laboratory radioimmunoassay accurately tracks response to chemotherapy treatment and disease status, the Malvern, Pennsylvania company claims. The assay will be distributed exclusively by Polymedco...
You may also be interested in...
Fujirebio Diagnostics plans to develop a multiplex assay for early detection of ovarian cancer that combines mesothelin and HE4 markers with the firm's CA 125 II serum-based assay
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.